Virax Biolabs Group Ltd (VRAX) stock
VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Mar 31, 2026Last filing: 20-F on Jul 6, 2026Score 9/30
$0.43−0.02 (-3.39%)
Close on Nov 18, 2026Market cap $249.06KP/E –Yield –
Virax Biolabs operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
For fiscal 2026 it was -$4.62M. The highest annual figure on record is -$590.19K in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -$4.62M | – |
| FY2025 | Mar 31, 2025 | -$4.56M | – |
| FY2024 | Mar 31, 2024 | -$6.40M | – |
| FY2023 | Mar 31, 2023 | -$4.18M | – |
| FY2022 | Mar 31, 2022 | -$809.07K | – |
| FY2021 | Mar 31, 2021 | -$590.19K | – |
See a number that looks wrong?